Efficacy of memantine on behavioral and psychological symptoms related to dementia: A systematic meta-analysis

Annals of Pharmacotherapy

Volumn 42, Issue 1, 2008, Pages 32-38

  Maidment, Ian D ^a,b   Fox, Chris G ^a,b   Boustani, Malaz ^c,d,e   Rodriguez, Jorge ^b   Brown, Ruth C ^a   Katona, Cornelius L ^a,b  

^a KENT AND MEDWAY NHS AND SOCIAL CARE PARTNERSHIP TRUST   (United Kingdom)

^b UNIVERSITY OF KENT   (United Kingdom)

^c Regenstrief Institute

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e INDIANA UNIVERSITY CENTER FOR AGING RESEARCH   (United States)

Author keywords

Alzheimer's disease; Dementia; Memantine

Indexed keywords

CHOLINESTERASE INHIBITOR; MEMANTINE; OLANZAPINE; PLACEBO; RISPERIDONE;

ALZHEIMER DISEASE; ARTICLE; BEHAVIOR DISORDER; CLINICAL TRIAL; DEMENTIA; DISEASE ASSOCIATION; DRUG EFFICACY; HUMAN; MENTAL DISEASE; META ANALYSIS; NEUROPSYCHIATRY; OUTCOMES RESEARCH; PRIORITY JOURNAL; SOMNOLENCE; SYMPTOMATOLOGY; SYSTEMATIC REVIEW;

AGED; ALZHEIMER DISEASE; BEHAVIORAL SYMPTOMS; DEMENTIA; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; MALE; MEMANTINE; MODELS, STATISTICAL; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 38049005871     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K372     Document Type: Article

References (26)

1. Lyketsos CG, Sheppard JE, Steinberg M, et al. Neuropsychiatric disturbance in Alzheimer's disease clusters into three groups: the Cache County study. Int J Geriatr Psychiatry 2001;16:1043-53.
2. Boustani M, Peterson B, Hanson L, Harris R. Screening for dementia. Systematic evidence review. Rockville, MD: Agency for Healthcare Research and Quality, 2002. www.ahrq.gov/clinic/uspstfix.htm (accessed 2007 Feb 10).
3. Boustani M, Ham RJ. Alzheimer disease and other dementias. In: Ham RJ, Sloane PD, Warshaw GA, et al., eds. Primary care geriatrics, a case-based approach. 5th ed. Philadelphia: Elsevier Mosby, 2007:219-36.
4. Boustani M, Zimmerman S, Williams CS, et al. Characteristics associated with behavioral symptoms related to dementia in long-term care residents. Gerontologist 2005;45:56-61.
5. Gruber-Baldini AL, Boustani M, Sloane PD, Zimmerman S. Behavioral symptoms in residential care/assisted living facilities: prevalence, risk factors, and medication management. J Am Geriatr Soc 2004;52:1610-7.
6. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 2005;293:596-608.
7. Trinh N-H, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer's disease: a meta-analysis. JAMA 2003;289:210-6.
8. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006;355:1525-38.
9. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drag treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005;294:1934-43.
10. Livingston G, Johnston K, Katona C, Paton J, Lyketsos CG. Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. Am J Psychiatry 2005;162:1996-2021.
11. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gombein J. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308-14.
12. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Task Force on Alzheimer's disease. Neurology 1984;34:939-44.
13. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. JAMA 2004;291:317-24.
14. Peskind ER, Potkin SG, Pomara N, et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized controlled trial. Am J Geriatr Psychiatry 2006;14:704-15.
15. Forest Clinical Trials Register. www.forestclinicaltrials.com/CTR/ CTRController/CTRViewPdf?_file_id=scsr/SCSR_MEM-MD-12_final.pdf (accessed 2007 Feb 8).
16. Forest Clinical Trials Register. www.forestclinicaltrials.com/CTR/ CTRController/CTRViewPdf?_file_id=scsr/SCSR_MEM-MD-01_final.pdf (accessed 2007 Feb 7).
17. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333-41.
18. Bakchine S, Pascual-Gangnant L, Loft H. Results of a randomised, placebo-controlled 6-month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. Presented at: 18th Congress of the European College of Neuropsychopharmacology, Amsterdam, 2005.
19. Forest Clinical Trials Register. www.forestclinicaltrials.com/CTR/ CTRController/CTRViewPdf?_file_id=scsr/SCSR_MEM-MD-10_final.pdf (accessed 1 Apr 2007).
20. Forest Clinical Trials Register. www.forestclinicaltrials.com/CTR/ CTRController/CTRViewPdf?_file_id=scsr/SCSR_MEM-MD-02_final.pdf (accessed 1 Apr 2007).
21. McShane R, Areosa Sastre A, Minakaran N. Review - memantine for dementia. Cochrane Database Systematic Rev 2007(1). Cochrane Collaboration. John Wiley & Sons, Ltd., 2006. DOI 10.1002/14651858.CD003154.pub5
22. Ballard C, Waite J, Birks J. Atypical antipsychotics for aggression and psychosis in Alzheimer's disease. Cochrane Database Systematic Rev 2006(1). Cochrane Collaboration. John Wiley & Sons, Ltd., 2006. DOI 10.1002/14651858.CD003476.pub2
23. National Institute for Clinical Excellence. Technology Appraisal 111. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease. November 2006. www.nice.org.uk/guidance/TA111/guidance/ pdf/English (accessed 8 Feb 2007)
24. Streiner DL. The case of the missing data: methods of dealing with dropouts and other research vagaries. Can J Psychiatry 2002;47:68-75.
25. International Standard Randomized Controlled Trial Number (ISRCTN) Register. Memantine agitation in dementia (MAGD) 24953404. www.controlled- trials.com/ISRCTN24953404 (accessed 12 Feb 2007).
26. Cummings JL, Schneider E, Tariot PN, Graham SM. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology 2006;67:57-63.